Diferencias y estabilidad diagnóstica entre trastornos psicóticos inducidos por sustancias y trastornos psicóticos no inducidos

Julia Cambra Almerge, Sergio Sánchez-Romero, Francisco Arias Horcajadas

Resumen


Se han propuesto distintas hipótesis para explicar la comorbilidad entre trastornos psicóticos y por consumo de sustancias, siendo una de ellas la capacidad de algunas de inducir cuadros psicóticos, aunque la transición de episodios psicóticos inducidos por sustancias a esquizofrenia ha sido menos estudiada. En este trabajo se determinan variables diferenciales entre individuos con psicosis inducidas y no inducidas, y se analiza la evolución y el cambio de diagnóstico de las inducidas a esquizofrenia en el seguimiento. Es un estudio observacional de casos y controles con 238 pacientes ingresados en la unidad de agudos de un Hospital General de Madrid (España) por episodios psicóticos entre diciembre de 2003 y septiembre de 2011. Se incluyeron 127 en el grupo de trastornos psicóticos no inducidos por sustancias (TPNIS) y 111 en el de inducidos por sustancias (TPIS), según la Clasificación Internacional de Enfermedades. Se compararon características sociodemográficas, clínicas, antecedentes personales y familiares, de consumo de sustancias, estabilidad diagnóstica y evolución. El grupo de TPNIS presentó mayores puntuaciones en gravedad y sintomatología negativa mientras que el de TPIS tuvo más antecedentes personales de trastorno de personalidad y familiares de adicciones, y más sintomatología positiva. A los seis años un 40,9% de TPIS cambió a diagnóstico de esquizofrenia, presentando más antecedentes familiares de trastornos psicóticos y de adicciones, y una peor evolución con más visitas a urgencias y reingresos que los sujetos con estabilidad diagnóstica. Por tanto, habrá que prestar especial atención a este grupo de sujetos por su potencial gravedad y por el mayor riesgo de desarrollar un trastorno psicótico crónico.


Palabras clave


trastorno psicótico inducido por sustancias; psicosis; adicción; esquizofrenia; estabilidad diagnóstica

Texto completo:

PDF PDF (English)

Referencias


Abdel-Baki, A., Ouellet-Plamondon, C., Salvat, É., Grar, K. & Potvin, S. (2017). Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Research247, 113-119. doi:10.1016/j.psychres.2016.11.007.

Alderson, H. L., Semple, D. M., Blayney, C., Queirazza, F., Chekuri, V. & Lawrie, S. M. (2017). Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. Psychological Medicine47, 2548-2555. doi:10.1017/S0033291717001118.

Arendt, M., Rosenberg, R., Foldager, L., Perto, G. & Munk-Jorgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. The British Journal of Psychiatry, 187, 510-515. doi:10.1192/bjp.187.6.510.

Arias, F., Szerman, N., Vega, P., Mesías, B., Basurte, I., Morant, C., … Babín, F. (2013). Estudio Madrid sobre prevalencia y características de los pacientes con patología dual en tratamiento en las redes de salud mental & de atención al drogodependiente. Adicciones, 25, 118-127.

Baldacchino, A., Hughes, Z., Kehoe, M., Blair, H., Teh, Y., Windeatt, S. & Crome, I. B. (2012). Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. The American Journal on Addictions21, S88-98. doi:10.1111/j.1521-0391.2012.00295.x.

Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., …

 Kish, S. J. (2012). Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry169, 389-396. doi:10.1176/appi.ajp.2011.10070937.

Cantor-Graae, E., Nordström, L. G. & McNeil, T. F. (2001). Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia Research48, 69-82. doi:10.1016/s0920-9964(00)00114-6.

Caton, C. L., Drake, R. E., Hasin, D. S., Dominguez, B., Shrout, P. E., Samet, S. & Schanzer, B. (2005). Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry62, 137-145. doi:10.1001/archpsyc.62.2.137.

Caton, C. L., Hasin, D. S., Shrout, P. E., Drake, R. E., Dominguez, B., First, M. B., … Schanzer, B. (2007). Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. The British Journal of Psychiatry, 190, 105-111. doi:10.1192/bjp.bp.105.015784.

Chambers, R. A., Krystal, J. H. & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71-83. doi:10.1016/s0006-3223(01)01134-9.

Chaudhury, S., Krishna, S. T. & Kumar, A. B. (2016). Impact of substance use disorder on presentation of schizophrenia. Dual Diagnosis Open Access, 1, 7. doi:10.21767/2472-5048.100007.

Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., Loh, E. W., Hsiao, C. C., … Murray, R. M. (2003). Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine33, 1407-1414. doi:10.1017/S0033291703008353.

Chen, W. L., Hsieh, C. H., Chang, H. T., Hung, C. C. & Chan C. H. (2015). The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan. Addictive Behaviors, 47, 1-4. doi:10.1016/j.addbeh.2015.02.013.

Crebbin, K., Mitford, E., Paxton, R. & Turkington, D. (2009). First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Social Psychiatry and Psychiatric Epidemiology, 44, 710-715. doi:10.1007/s00127-008-0490-2.

Fiorentini, A., Volonteri, L. S., Dragogna, F., Rovera, C., Maffini, M., Mauri, M. C. & Altamura, C. A. (2011). Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews4, 228-240. doi:10.2174/1874473711104040228.

Fonseca-Pedrero, E., Lucas-Molina, B., Pérez-Albéniz, A., Inchausti, F. &Ortuño-Sierra, J. (2020). Psychotic-like experiences and cannabis use inadolescents from the general population. Adicciones, 32, 41-51. doi:10.20882/adicciones.1149.

Fraser, S., Hides, L., Philips, L., Proctor, D. & Lubman, D. I. (2012). Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophrenia Research, 136 110-115. doi:10.1016/j.schres.2012.01.022.

Fusar-Poli, P., Cappucciati, M., Rutigliano, G., Heslin, M., Stahl, D., Brittenden, Z., … Carpenter, W. T. (2016). Diagnostic stability of ICD/DSM first episode psychosis diagnoses: meta-analysis. Schizophrenia Bulletin42, 1395-1406. doi:10.1093/schbul/sbw020.

Gage, S. H., Hickman, M. & Zammit, S. (2016). Association between cannabis and psychosis: epidemiologic evidence. Biological Psychiatry,

79, 549–56. doi:10.1016/j.biopsych.2015.08.001.

García Álvarez, L., Gomar, J. J., García-Portilla, M. P. & Bobes, J. (2019). Cannabis use and cognitive impairment in schizophrenia and first-episodepsychosis. Adicciones, 31, 89-94. doi:10.20882/adicciones.1328.

Gregg, L., Barrowclough, C. & Haddock, G. (2007). Reasons for increased substance use in psychosis. Clinical Psychology Review,

27, 494-510. doi:10.1016/j.cpr.2006.09.004.

IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.

Kadouri, A., Coeeuble, E. & Falissard B. (2007). The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry, 7, 1. doi: 10.1186/1471-244X-7-7.

Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276. doi:10.1093/schbul/13.2.261.

Kay, S. R., Opler, L. A. & Lindenmayer, J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry. Supplement, 7, 59-67.

Kay, S. R. & Sevy, S. (1990). Pyramidical model of schizophrenia. Schizophrenia Bulletin,

16, 537-545. doi:10.1093/schbul/16.3.537

Keshavan, M. S. & Kaneko Y. (2013). Secondary psychoses: an update. World Psychiatry, 12, 4-15. doi:10.1002/wps.20001.

Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Review of Psychiatry4, 231-244. doi:10.3109/10673229709030550.

Latt, N., Jurd, S., Tennant, C., Lewis, J., Macken, L., Joseph, A., … Long, L. (2011). Alcohol and substance use by patients with psychosis presenting to an emergency department: changing patterns. Australasian Psychiatry19, 354-359. doi:10.3109/10398562.2011.579971.

Mathias, S., Lubman, D. I. & Hides, L. (2008). Substance-induced psychosis: a diagnostic conundrum. The Journal of Clinical Psychiatry69, 358-367. doi:10.4088/jcp.v69n0304.

Mauri, M. C., Di Pace, C., Reggiori, A., Paletta, S. & Colasanti, A. (2017). Primary psychosis with comorbid drug abuse and drug-induced psychosis: diagnostic and clinical evolution at follow up, Asian Journal of Psychiatry, 29, 117-122. doi:10.1016/j.ajp.2017.04.014.

Møller, T. & Linaker, O. M. (2004). Symptoms and lifetime treatment experiences in psychotic patients with and without substance abuse. Nordic Journal of Psychiatry,

58, 237-242. doi:10.1080/08039480410006296.

Moshe, L. B., Weizman, A., Ben, D. H., Konas, S., Fischel, Z., Aizenberg, D., … Valevski, A. (2018). Differences in demographic and clinical characteristics between cannabis users and non-drug users: a retrospective study of patients with first hospitalization due to psychotic symptoms, Psychiatry Research,

268, 454-459. doi:10.1016/j.psychres.2018.07.037.

Myles, N., Newall, H., Nielssen, O. & Large, M. (2012). The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current Pharmaceutical Design, 18, 5055-5069. doi:10.2174/138161212802884816.

Myles, H., Myles, N. & Large, M. (2015). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Australian and New Zealand Journal of Psychiatry,

50, 208-219. doi:10.1177/0004867415599846.

Niemi-Pynttäri, J. A., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K. & Pirkola, S.P. (2013). Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. The Journal of Clinical Psychiatry74, e94-9. doi:10.4088/JCP.12m07822.

Núñez, L. A. & Gurpegui, M. (2002). Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica105, 173-178. doi:10.1034/j.1600-0447.2002.1o079.x.

Organización Mundial de la Salud. (1992). CIE-10. Trastornos Mentales y del Comportamiento. Décima Revisión de la Clasificación Internacional de las Enfermedades. Descripciones Clínicas y pautas para el diagnóstico. Ginebra: Organización Mundial de la Salud.

Paparelli, A., Di Forti, M., Morrison, P. D. & Murray, R. M. (2011). Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Frontiers in Behavioral Neuroscience5, 1. doi:10.3389/fnbeh.2011.00001.

Pedrós, A., Martí

,

J., Gutiérrez, G., Tenías, J. M. & Ruescas, S. (2009). Two-year diagnostic stability and prognosis in acute psychotic episodes. Actas Españolas de Psiquiatría, 37, 245-251.

Peralta, V. & Cuesta, M. J. (1994). Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Research, 53, 31-40. doi:10.1016/0165-1781(94)90093-0.

Rodríguez-Jiménez, R., Bagney, A., Mezquita, L., Martínez-Gras, I., Sánchez-Morla, E. M., Mesa, N., … Palomo, T. (2013). Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophrenia Research, 143, 77-83. doi:10.1016/j.schres.2012.10.020.

Rognli, E. B., Berge, J., Håkansson, A. & Bramness, J. G. (2015). Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users. Schizophrenia Research168, 185-190. doi:10.1016/j.schres.2015.08.032.

Sara, G. E., Burgess, P. M., Malhi, G. S., Whiteford, H. A. & Hall, W. C. (2014). The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. The Journal of Clinical Psychiatry, 75, 349-356. doi:10.1016/j.schres.2015.08.032.

Schuckit, M. A. (2006). Comorbidity between substance use disorders and psychiatric conditions. Addiction,

 

101 (Suppl 1), 76-88. doi:10.1111/j.1360-0443.2006.01592.x.

Seddon, J. L., Birchwood, M., Copello, A., Everard, L., Jones, P. B., Fowler, D., … Sing, S. P. (2016). Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: a report from the UK national EDEN study. Schizophrenia Bulletin,

42, 619-625. doi:10.1093/schbul/sbv154.

Semple, D. M., McIntosh, A. M. & Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology19, 187-194. doi:10.1177/0269881105049040.

Shah, D., Chand, P., Bandawar, M., Benegal, V. & Murthy, P. (2017). Cannabis induced psychosis and subsequent psychiatric disorders. Asian Journal Psychiatry, 30, 180-184. doi:10.1016/j.ajp.2017.10.003.

Singal, A., Bhat, P. S., Srivastava, K. & Prakash, J. (2015). The study of primary psychotic disorders with concurrent substance abuse in terms of their diagnostic stability. Indian Journal of Psychiatry57, 224-228. doi:10.4103/0019-5545.166638.

Soyka, M. (2008). Prevalence of alcohol-induced psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience258, 317-318. doi:10.1007/s00406-008-0767-1.

Starzer, M. S. K., Nordentoft, M. & Hjorthøj, C. (2018). Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. American Journal of Psychiatry, 175, 343-350. doi:10.1176/appi.ajp.2017.17020223.

Thirthalli, J. & Benegal, V. (2006). Psychosis among substance users. Current Opinion in Psychiatry19, 239-245. doi:10.1097/01.yco.0000218593.08313.fd.

Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K., … Ruggeri, M. (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research,

47, 438-444. doi:10.1016/j.jpsychires.2012.11.009.

Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137, 246-250. doi:10.1016/j.schres.2012.01.031.

Weibell, M. A., Joa, I., Bramness, J., Johannessen, J. O., McGorry, P. D., Ten Velden Hegelstad, W. & Larsen, T. K. (2013). Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry13, 319. doi:10.1186/1471-244X-13-319.

Volkow, N. D. (2001). Drug abuse and mental illness: progress in understanding comorbidity. American Journal of Psychiatry158, 1181-1183. doi:10.1176/appi.ajp.158.8.1181.

Zawilska, J. B. & Wojcieszak, J. (2013). Designer cathinones-an emerging class of novel recreational drugs. Forensic Science International231, 42-53. doi:10.1016/j.forsciint.2013.04.015.




DOI: https://doi.org/10.20882/adicciones.1291

Enlaces refback

  • No hay ningún enlace refback.